Group 1 - The stock of Shangrong Medical (002551) closed at 3.86 yuan on November 27, 2025, with a market capitalization of 3.264 billion yuan, reflecting a 0.26% increase from the previous trading day [1] - The company announced the completion of the public issuance of convertible bonds on February 20, 2019, raising a total of 750 million yuan, with a net amount of 733 million yuan allocated for a "high-end medical consumables industrialization project" [1] - The board and shareholders approved the termination of the project on August 23 and September 12, 2025, with approximately 359 million yuan of the remaining funds being permanently allocated to supplement working capital [1] Group 2 - All funds from the five special accounts for the raised capital have been fully utilized, and the related accounts have been closed, with the tripartite supervision agreement also terminated [1]

证券之星消息，截至2025年11月27日收盘，尚荣医疗(002551)报收于3.86元，上涨0.26%，换手率 1.63%，成交量9.96万手，成交额3839.69万元。 11月27日的资金流向数据方面，主力资金净流出71.29万元，占总成交额1.86%，游资资金净流出183.02 万元，占总成交额4.77%，散户资金净流入254.31万元，占总成交额6.62%。 近5日资金流向一览见下表： | 指标 | 尚荣医疗 | 医疗器械行业均值 | 行业排名 | | --- | --- | --- | --- | | 总市值 | 32.64亿元 | 110.26亿元 | 99 124 | | 净资产 | 27.3亿元 | 38.93亿元 | 57 124 | | 净利润 | -3512.53万元 | 2.12亿元 | 111 124 | | 市盈率(动) | -69.69 | 56.75 | - 124 | | 市净率 | 1.26 | 3.87 | 15 124 | | 毛利率 | 14.35% | 51.22% | 119 124 | | 净利率 | -4.6% | 9.57% | 103 124 | | ROE ...

证券代码：002551 证券简称：尚荣医疗 公告编号：2025-052 关于公开发行可转换公司债券募集资金专户销户完成的 公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、募集资金基本情况 根据中国证券监督管理委员会于 2018 年 12 月 5 日签发的证监许可 [2018]1843 号文《关于核准深圳市尚荣医疗股份有限公司公开发行可转换公司债 券的批复》深圳市尚荣医疗股份有限公司（以下简称"公司"或"尚荣医疗"） 获准社会公开发行面值总额 75,000 万元的可转换公司债券，期限 6 年。公开发 行可转换公司债券应募集资金人民币 750,000,000.00 元，发行价格为每张人民币 100.00 元，募集资金总额为人民币 750,000,000.00 元。本次发行可转换公司债券 募集资金总额扣除保荐承销费用不含税金额 14,150,943.40 元，其他发行费用不 含税金额 2,502,830.20 元，实际募集资金净额为人民币 733,346,226.40 元，上述 资金于 2019 年 2 月 20 日到位，业经大华会计师事务所（特殊普通合伙 ...

Core Viewpoint - The stock of Shangrong Medical (002551) has shown a slight increase of 2.7% on November 24, 2025, closing at 3.81 yuan, despite facing significant net outflows from major and retail investors in recent days [1][2]. Financial Performance - Shangrong Medical reported a total revenue of 754 million yuan for the first three quarters of 2025, representing a year-on-year decline of 24.85% [3]. - The company recorded a net profit attributable to shareholders of -35.13 million yuan, a significant drop of 338.5% year-on-year [3]. - The third quarter of 2025 saw a single-quarter revenue of 225 million yuan, down 39.25% year-on-year, with a net profit of -27.37 million yuan, reflecting a staggering decline of 4004.28% [3]. Market Position - As of November 24, 2025, Shangrong Medical's total market capitalization stands at 3.22 billion yuan, which is significantly lower than the industry average of 10.98 billion yuan [3]. - The company's net asset value is 2.73 billion yuan, compared to the industry average of 3.89 billion yuan [3]. - Shangrong Medical's price-to-earnings ratio is -68.78, while the industry average is 55.96, indicating poor profitability [3]. Profitability Metrics - The gross margin for Shangrong Medical is 14.35%, which is substantially lower than the industry average of 51.22% [3]. - The net margin stands at -4.6%, compared to the industry average of 9.57% [3]. - Return on equity (ROE) is -1.34%, significantly below the industry average of 0.15% [3]. Recent Trading Activity - On November 24, 2025, the stock experienced a trading volume of 181,000 hands and a transaction value of 68.649 million yuan [1]. - The net outflow of major funds was 2.58 million yuan, accounting for 3.76% of the total transaction value, while retail investors saw a net inflow of 4.23 million yuan, representing 6.16% of the total [1][2].

编号：2025-003 投 资 者 关 系 活 动 类 别 □特定对象调研 □分析师会议 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 ■其他（2025 年度深圳辖区上市公司投资者网上集体接待日活动） 参 与 单 位 名 称 及 人 员姓名 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net）参与"2025 年度深圳辖区上市公司投资者网上集体接待日活动"的投资者 时间 2025 年 11 月 20 日 14:30-17:00 地点 全景路演（https://ir.p5w.net） 上 市 公 司 接 待 人 员 姓名 董事长、总经理：梁桂秋 副总经理、董事会秘书：林立 财务总监：游泳 独立董事：曾江虹 投 资 者 关 系 活 动 主 要 内 容 介 绍 本次投资者网上集体接待日活动采用网络远程的方式举行，主要问答内 容如下： 1、请问海外业务的毛利为什么年年下滑？ 您好，感谢您对公司的关注！受进出口关税变动及运输成本增加所致。 谢谢！ 2、董事长好，我是公司小微股民，请问一下，公司的未来五年规划是怎 么安排的？另外，我国已经进入老年化社会，公司在设计，建设，配套医疗 ...

证券日报网讯尚荣医疗11月19日在互动平台回答投资者提问时表示，公司将在定期报告中披露对应期末 时点的股东数量等信息，请后续关注公司的定期报告。 （文章来源：证券日报） ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002551 证券简称：尚荣医疗 公告编号：2025-051 深圳市尚荣医疗股份有限公司 关于参加2025年度深圳辖区上市公司投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 2025年11月18日 为进一步加强与投资者互动交流，深圳市尚荣医疗股份有限公司（以下简称"公司"）将参加由深圳证监 局和中证中小投资者服务中心指导、深圳上市公司协会与深圳市全景网络有限公司联合举办的"2025年 度深圳辖区上市公司投资者网上集体接待日活动" ，现将有关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net），或关注微信 公众号：全景财经，或下载全景路演APP,参与本次互动交流，活动时间为2025年11月20日（星期四） 14:30至17:00。届时公司高管将在线就公司业绩、公司治理、发展战略、经营状况、融资计划、股权激 励和可持续发展等投资者关心的问题，与投资者进行沟通与交流，欢迎广大投资者踊跃参与！ 特此公告。 深圳 ...

证券代码：002551 证券简称：尚荣医疗 公告编号：2025-051 深圳市尚荣医疗股份有限公司 关于参加 2025 年度深圳辖区上市公司投资者 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演APP, 参与本次互动交流，活动时间为2025年11月20日（星期四）14:30至17:00。届时 公司高管将在线就公司业绩、公司治理、发展战略、经营状况、融资计划、股权 激励和可持续发展等投资者关心的问题，与投资者进行沟通与交流，欢迎广大投 资者踊跃参与！ 特此公告。 深圳市尚荣医疗股份有限公司 董 事 会 2025年11月18日 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 为进一步加强与投资者互动交流，深圳市尚荣医疗股份有限公司（以下简称 "公司"）将参加由深圳证监局和中证中小投资者服务中心指导、深圳上市公司 协会与深圳市全景网络有限公司联合举办的"2025年度深圳辖区上市公司投资 者网上集体接待日活动" ，现将有关事项公告如下： ...

Core Viewpoint - The financial performance of Shangrong Medical (002551) shows significant declines in revenue and profit, indicating potential challenges in the medical device industry [3]. Financial Performance - As of November 12, 2025, Shangrong Medical's stock closed at 4.08 yuan, with a slight increase of 0.25% and a trading volume of 127,400 hands, amounting to a total transaction value of 51.94 million yuan [1]. - In the third quarter of 2025, the company reported a main revenue of 225 million yuan, a year-on-year decrease of 39.25%, and a net profit attributable to shareholders of -27.37 million yuan, a decline of 4004.28% [3]. - For the first three quarters of 2025, the company's main revenue was 754 million yuan, down 24.85% year-on-year, with a net profit of -35.13 million yuan, a decrease of 338.5% [3]. Market Position - Shangrong Medical's total market capitalization is 3.45 billion yuan, significantly lower than the industry average of 11.669 billion yuan, ranking 124th in the industry [3]. - The company's net asset value stands at 2.73 billion yuan, compared to the industry average of 3.893 billion yuan, also ranking 124th [3]. - The company's gross margin is 14.35%, which is substantially below the industry average of 51.22%, ranking 119th [3]. Capital Flow - On November 12, 2025, the net inflow of main funds was 1.23 million yuan, accounting for 2.37% of the total transaction value, while retail investors experienced a net outflow of 1.19 million yuan, representing 2.28% of the total transaction value [1][2]. - Over the past five days, the main funds showed fluctuating trends, with a peak net inflow of 3.06 million yuan on November 11, 2025, and a significant net outflow of 3.57 million yuan on November 7, 2025 [2].

Core Viewpoint - The stock of Shangrong Medical (002551) has shown a slight increase of 1.5% on November 10, 2025, closing at 4.05 yuan, despite facing significant declines in revenue and profit in recent quarters [1][3]. Financial Performance - For the first three quarters of 2025, Shangrong Medical reported a main revenue of 754 million yuan, a year-on-year decrease of 24.85% [3]. - The net profit attributable to shareholders was -35.13 million yuan, representing a year-on-year decline of 338.5% [3]. - The third quarter alone saw a main revenue of 225 million yuan, down 39.25% year-on-year, with a net profit of -27.37 million yuan, a staggering decline of 4004.28% [3]. - The company’s debt ratio stands at 23.31%, with an investment income of 10.20 million yuan and financial expenses of -3.79 million yuan [3]. Market Position - Shangrong Medical's total market capitalization is 3.424 billion yuan, significantly lower than the industry average of 11.616 billion yuan, ranking 102 out of 124 in the medical device industry [3]. - The company has a negative price-to-earnings ratio of -73.12, compared to the industry average of 62.58, indicating poor profitability [3]. - The gross margin is reported at 14.35%, which is substantially below the industry average of 51.22%, ranking 119 out of 124 [3]. Capital Flow Analysis - On November 10, 2025, the net inflow of main funds was 1.90 million yuan, accounting for 3.19% of the total transaction amount, while retail investors saw a net inflow of 1.99 million yuan, making up 3.33% [1][2]. - In contrast, speculative funds experienced a net outflow of 3.89 million yuan, representing 6.52% of the total transaction amount [1][2]. - Over the past five days, the stock has seen fluctuating capital flows, with notable outflows from speculative funds on several days [2].